Company: CMND
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005519
Chunk: 13

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: POS AM
Chunk 13
---
5, and does not include the following as of that date:

| ● | 2,238,848 common shares issuable upon the exercise                                                                                 
 of warrants outstanding as of such date, at exercise prices ranging from $1.0777 to $1,293.48, all of which were vested as of such 
 date;                                                                                                                              |
| ● | 5,521 common shares issuable upon the exercise of                                                                                  
 options to directors, employees and consultants under our incentive option plan outstanding as of such date, at a weighted average 
 exercise price of $432.38, of which 5,351 were vested as of such date; and                                                         |
| ● | 146,292 common shares issuable upon the exercise                                                                                   
 of restricted share units issued to consultants under consulting agreements.                                                       |

Unless otherwise indicated, all information in this prospectus assumes or gives effect to no exercise of the warrants or options described above See “Description of Share Capital” for additional information.

<div align='center'>4

RISK FACTORS</div>

You should carefully consider the risks described below and the risks described in our 2024 Annual Report which are incorporated by reference herein, as well as the financial or other information included in this prospectus or incorporated by reference in this prospectus, including our consolidated financial statements and the related notes, before you decide to buy our securities. The risks and uncertainties described below are not the only risks facing us. We may face additional risks and uncertainties not currently known to us or that we currently deem to be immaterial. Any of the risks described below, and any such additional risks, could materially adversely affect our business, financial condition or results of operations. In such case, you may lose all or part of your original investment.

The sale of a substantial amount of our ordinary shares, including resale of the ordinary shares issuable upon the exercise of the warrants held by the selling shareholders in the public market could adversely affect the prevailing market price of our ordinary shares.

We are registering for resale an aggregate
of 1,126,480 common shares issuable upon the exercise of warrants held by the selling shareholders. Sales of substantial amounts of our
common shares in the public market, or the perception that such sales might occur, could adversely affect the market price of our common
shares, and the market value of our other securities. We cannot predict if and when selling shareholders may sell such shares in the
public markets. Furthermore, in the future, we may issue additional common shares or other equity or debt